Document is current
Any future updates will be listed below
-
Authors
Nishiwaki, Satoshi
Ando, Yuichi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP17K16186)
- License Information
-
More Information
Article History
Received: 28 May 2020
Accepted: 4 September 2020
First Online: 13 October 2020
Competing interests
: Yuichi Ando reports grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Kyowa Hakko Kirin Co., Ltd., grants and personal fees from Nippon Kayaku Co., Ltd., grants and personal fees from Yakult Honsha Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Mochida Pharmaceutical Co., Ltd., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Novartis Pharma K.K., personal fees from Merck Serono Co., Ltd., personal fees from Bayer Holding Ltd., personal fees from Bristol-Myers Squibb, personal fees from Otsuka Holdings Co., Ltd., personal fees from Sawai Pharmaceutical Co., Ltd, grants and personal fees from Daiichi Sankyo Company, Ltd., grants from Eisai Co., Ltd., grants from Hisamitsu Pharmaceutical Co., Inc., grants from Takeda Pharmaceutical Co., Ltd., personal fees from Tsumura & Co., personal fees from Shionogi & Co., Ltd, personal fees from Janssen Pharmaceutical K.K., personal fees from Pharma International Inc., outside the submitted work. Satoshi Nishiwaki has no competing interest to disclose.
